Expression analysis of cytoskeleton regulator RNA and Cyclin Dependent Kinase Inhibitor 2B genes in breast cancer

Article type: Research Article

Authors: Mokhtari, Majid^a | Gholipour, Mahdi^b | Eslami, Solat^{c; d} | Abak, Atefe^e | Hussen, Bashdar Mahmud^f | Rakhshan, Azadeh^{g; *} | Ghafouri-Fard, Soudeh^{h; *}

Affiliations: [a] Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [b] Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [c] Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran | [d] Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran | [e] Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [f] Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Kurdistan Region, Erbil, Iran | [g] Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran | [h] Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence: [*] Corresponding authors: Azadeh Rakhshan, Department of Pathology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail: azadehrakhshan@yahoo.com.SoudehGhafouri-Fard,DepartmentofMedicalGenetics,SchoolofMedicine,ShahidBeheshtiUniversityofMedicalSciences,Tehran,Iran.E-mail:s.ghafourifard@sbmu.ac.ir.

Abstract: BACKGROUND: Breast cancer has been found to be associated with deregulation of several non-coding genes and mRNA coding genes. OBJECTIVE: To assess expressions of CYTOR and CDKN2B in breast cancer and adjacent samples and find their relevance with clinical data. METHODS: We enumerated expression level of CDKN2B and CYTOR in 43 newly diagnosed breast cancer samples and their adjacent specimens using real-time PCR method Expression data was judged using Wilcoxon matched-pairs signed rank test. RESULTS:CYTOR level was higher in tumors compared with adjacent tissues. Nevertheless, there was no difference in expression of CDKN2B between these two sets of tissues. ROC curve analysis showed that CYTOR levels can differentiate between tumoral and adjacent tissues with AUC, specificity and sensitivity values of 0.65, 37% and 92% (P= 0.017). There was a positive correlation between expression levels of CYTOR and CDKN2B genes in breast cancer tissues (r= 0.5 and P= 0.0008) as well as adjacent tissues (r= 0.79 and P< 0.0001). Relative expression level of CDKN2B in normal tissues was associated with clinical stage (P= 0.014). Moreover, relative expression level of CDKN2B in tumor tissues was associated with the body weight. There was no other association between expressions of CYTOR and CDKN2B and clinical or pathological variables. CONCLUSIONS: Cumulatively, this study offers evidence for involvement of these genes in the pathoetiology of breast cancer.

Keywords: Breast cancer, CYTOR, CDKN2B

DOI: 10.3233/HAB-220015

Journal: Human Antibodies, vol. 31, no. 3, pp. 51-57, 2023